Ratings Myomo, Inc.

Equities

MYO

US62857J2015

Market Closed - Nyse Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
3.78 ^USD	+5.59%		-3.82%	-24.55%

05-08	Transcript : Myomo, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08	Myomo, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
MYOMO, INC.	-24.55%	109M	-
ABBOTT LABORATORIES	-4.98%	182B	C+
MEDTRONIC PLC	+2.84%	112B	C
BECTON, DICKINSON AND COMPANY	-2.68%	68.58B	A
DEXCOM, INC.	+4.53%	51.58B	B-
CENCORA, INC.	+8.00%	44.24B	B-
HOYA CORPORATION	+9.65%	43.65B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.30%	32.46B	B
WEST PHARMACEUTICAL SERVICES, INC.	-0.17%	25.61B	A-
TERUMO CORPORATION	+21.57%	25.99B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes